The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, talks about one of the arms of the Phase IIIb GREEN clinical trial, of obinutuzumab (GA101) plus bendamustine in chronic lymphocytic leukemia (CLL) patients, presented at the American Society of Hematology (ASH) 2015 Annual Meeting. Patients in this arm had a complete remission rate of 40%, and the majority of them achieved minimum residual disease (MRD) negativity in the blood and approx. 50% were MRD negative in the bone marrow.
